The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Any derivative of a non-proteinogenic amino acid resulting from reaction at an amino group or carboxy group, or from the replacement of any hydrogen by a heteroatom.
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]
IDH2 protein mutant form results in increased abundance of Pantothenic Acid Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Pantothenic Acid]
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA
SLC5A6 results in increased transport of Pantothenic Acid Sodium affects the reaction [SLC5A6 results in increased transport of Pantothenic Acid] Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Pantothenic Acid]
Methylphenidate affects the expression of BDNF mRNA [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein] Methylphenidate results in decreased expression of BDNF mRNA
[CES1 protein results in increased hydrolysis of Methylphenidate] which results in increased chemical synthesis of ritalinic acid; Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; CES1 gene mutant form results in decreased metabolism of and results in increased abundance of Methylphenidate; Fluoxetine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Thioridazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] CES1 protein results in increased metabolism of Methylphenidate
[Fluoxetine co-treated with Methylphenidate] results in increased expression of CREB mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of CREB protein Methylphenidate results in decreased expression of CREB mRNA
[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Methylphenidate Methylphenidate results in decreased expression of DRD2 mRNA Methylphenidate affects the expression of DRD2 protein
[Fluoxetine co-treated with Methylphenidate] results in increased expression of EGR1 mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of EGR1 mRNA]; Methylphenidate promotes the reaction [Amphetamine results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of EGR1 mRNA]
[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] Methylphenidate results in increased expression of FOS mRNA [Fluoxetine co-treated with Methylphenidate] results in increased expression of FOS mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of FOS mRNA] Methylphenidate results in increased expression of FOS protein Methylphenidate results in decreased expression of FOS protein SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein] Methylphenidate results in increased expression of FOS mRNA; Methylphenidate results in increased expression of FOS protein
Methylphenidate results in increased expression of HOMER1 mRNA SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of HOMER1 mRNA]
Methylphenidate results in decreased expression of MAPK1 mRNA [Fluoxetine co-treated with Methylphenidate] results in increased expression of MAPK1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MAPK1 protein
[Fluoxetine co-treated with Methylphenidate] results in increased expression of MTOR mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MTOR protein Methylphenidate affects the expression of MTOR mRNA
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]
[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] Methylphenidate results in decreased expression of SLC6A3 mRNA Methylphenidate results in decreased expression of SLC6A3 protein SLC6A3 protein results in increased susceptibility to Methylphenidate SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein] SLC6A3 3' UTR polymorphism affects the susceptibility to Methylphenidate; SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate
Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]
N-Methylaspartate results in increased phosphorylation of ELAVL1 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Methylaspartate results in increased phosphorylation of ELAVL1 protein]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; Go 6976 inhibits the reaction [N-Methylaspartate results in increased phosphorylation of ELAVL1 protein]
N-Methylaspartate results in increased expression of MAPK1 protein modified form thieno(2,3-c)isoquinolin-5-one inhibits the reaction [N-Methylaspartate results in increased expression of MAPK1 protein modified form]
N-Methylaspartate results in increased expression of MAPK3 protein modified form thieno(2,3-c)isoquinolin-5-one inhibits the reaction [N-Methylaspartate results in increased expression of MAPK3 protein modified form]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; Dizocilpine Maleate inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; Dizocilpine Maleate inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; Go 6976 inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; Go 6976 inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein
Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]
Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]
Calcium Chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein]
AHR protein results in increased abundance of S-Adenosylhomocysteine PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine]
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]
S-Adenosylhomocysteine results in increased expression of APP protein S-Adenosylhomocysteine results in decreased methylation of APP promoter Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]; S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein
S-Adenosylhomocysteine results in decreased activity of DNMT1 protein S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter]
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]
S-Adenosylhomocysteine results in increased expression of MMP2 mRNA; S-Adenosylhomocysteine results in increased expression of MMP2 protein S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter] U 0126 inhibits the reaction [S-Adenosylhomocysteine results in increased expression of MMP2 protein]
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]; S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter] S-Adenosylhomocysteine results in decreased expression of OGG1 mRNA; S-Adenosylhomocysteine results in decreased expression of OGG1 protein
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] S-Adenosylhomocysteine results in increased expression of PSEN1 protein
[S-methylthiocitrulline results in decreased activity of NOS1 protein] which affects the susceptibility to Methamphetamine [S-methylthiocitrulline results in decreased activity of NOS1 protein] which affects the abundance of Sodium
S-methylthiocitrulline inhibits the reaction [Methamphetamine results in decreased activity of SLC18A2 protein]; S-methylthiocitrulline inhibits the reaction [Methamphetamine results in decreased expression of SLC18A2 protein]
AIFM1 protein inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased reduction of Glutathione]; AIFM1 protein promotes the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased reduction of Adenine Nucleotides]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]; wortmannin promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]
S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of BAD protein Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of BAD protein]
S-Nitroso-N-Acetylpenicillamine results in increased expression of BAX protein Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased expression of BAX protein]
Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein] S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 mRNA; S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased activity of and results in increased cleavage of CASP1 protein
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of CASP3 protein] S-Nitroso-N-Acetylpenicillamine results in increased activity of CASP3 protein S-Nitroso-N-Acetylpenicillamine results in decreased activity of CASP3 protein Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased activity of CASP3 protein]
S-Nitroso-N-Acetylpenicillamine inhibits the reaction [3,5-dimethoxy-4'-hydroxystilbene results in decreased phosphorylation of CREB1 protein]; S-Nitroso-N-Acetylpenicillamine inhibits the reaction [Quercetin results in decreased phosphorylation of CREB1 protein]
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein]; Uric Acid inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein]; Uric Acid inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein]
GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased activity of SOD1 protein]]; GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in increased activity of SOD2 protein]]; GPX1 protein affects the susceptibility to [Diquat co-treated with S-Nitroso-N-Acetylpenicillamine]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased expression of GPX1 protein]
S-Nitroso-N-Acetylpenicillamine results in decreased expression of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK1 protein]
S-Nitroso-N-Acetylpenicillamine results in decreased expression of MAPK3 protein S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein]
S-Nitroso-N-Acetylpenicillamine results in decreased activity of NOS2 protein S-Nitroso-N-Acetylpenicillamine results in decreased expression of NOS2 promoter
[S-Nitroso-N-Acetylpenicillamine co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of NPR3 protein]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCA protein]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to RAF1 protein]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to RGS17 protein]
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]
[S-Nitroso-N-Acetylpenicillamine co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] S-Nitroso-N-Acetylpenicillamine results in increased activity of PRKG1 protein
S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA]; PD 156707 inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA]
bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPB mRNA]; PD 156707 inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPB mRNA]
bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPC mRNA]; PD 156707 inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPC mRNA]
GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased activity of SOD1 protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased activity of SOD1 protein] SOD1 protein affects the susceptibility to S-Nitroso-N-Acetylpenicillamine
GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in increased activity of SOD2 protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in increased activity of SOD2 protein] [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of TRP53 mRNA S-Nitroso-N-Acetylpenicillamine promotes the reaction [FGF2 protein results in increased expression of TP53 protein]
S-Nitroso-N-Acetylpenicillamine results in increased expression of VEGFA mRNA S-Nitroso-N-Acetylpenicillamine results in increased secretion of VEGFA protein
browse the term
